Related Experiment Video
Updated: Mar 14, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
[Comorbidities affecting abiraterone treatment in patients with metastatic castration-resistant prostate cancer: a
Barna Budai1, Bertalan Fekete2, Krisztina Biró3
1Molekuláris Genetikai Osztály, Országos Onkológiai Intézet, Budapest, Hungary. budai.barna@oncol.hu.
Aim:
Optimizing the treatment of metastatic prostate cancer is important for reducing mortality. Therefore, it is essential, among others, to know the predictive markers of abiraterone acetate (AA) treatment in metastatic castration-resistant prostate cancer (mCRPC). We aimed to clarify the predictive factors of AA treatment of mCRPC patients, and particularly the predictive role of comorbidities and co-medication based on meta-analysis of published data.
Methods:
Meta-analysis of the results of multivariate analysis found in 120 publications examining at least 100 cases.
Results:
Besides clear predictors of progression-free and overall survival, opioid use, pain, cerebrovascular diseases, dyslipidemia, statin treatment, bisphosphonate/antiresorptive treatment and metabolic syndrome significantly affect the risk of progression and survival.
Conclusions:
Since the analysis of comorbidities is based on relatively few observations, further studies are needed to clarify the predictive impact of comorbidities and co-medication in order to improve the effectiveness of treatment in mCRPC in an individualized manner.
Related Concept Videos
02:56Treatment Resistent Cancers
02:56Treatment Resistant Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...